Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Rare Cancers Ther (2013) 1:3–19 DOI 10.1007/s40487-013-0002-8 REVIEW Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Mohamed E. Salem Sherif M. El-Refai To view enhanced content go to www.rarecancers-open.com Received: July 23, 2013 / Published online: October 16, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Methods: A search of PubMed and MEDLINE ABSTRACT from January 2000 to August 2013 was Background: Vascular endothelial growth performed using the following terms (or factor (VEGF) and related pathway elements combination of terms): VEGF, colorectal are critically important in the pathogenesis, cancer, mCRC, aflibercept, ziv-aflibercept. growth, and development of solid tumors. Studies were limited to those published in Inhibiting the VEGF signaling pathway is English. being investigated as a therapeutic strategy for Results: Phase 1 and 2 clinical trials of cancer, either by blockade of VEGF ligand aflibercept in advanced non-hematological binding or inhibition of the VEGF receptor. cancer showed acceptable safety and provided Aflibercept is a VEGF inhibitor that has been justification for further investigation. Four approved by the US Food and Drug phase 3 clinical trials were conducted to Administration for the treatment of macular evaluate aflibercept for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer

Oncology and Therapy , Volume 1 (2) – Oct 16, 2013

Loading next page...
 
/lp/springer-journals/efficacy-and-safety-of-aflibercept-and-its-role-in-the-treatment-of-Fe97Y91J4o
Publisher
Springer Journals
Copyright
Copyright © 2013 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-013-0002-8
Publisher site
See Article on Publisher Site

Abstract

Rare Cancers Ther (2013) 1:3–19 DOI 10.1007/s40487-013-0002-8 REVIEW Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer Mohamed E. Salem Sherif M. El-Refai To view enhanced content go to www.rarecancers-open.com Received: July 23, 2013 / Published online: October 16, 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Methods: A search of PubMed and MEDLINE ABSTRACT from January 2000 to August 2013 was Background: Vascular endothelial growth performed using the following terms (or factor (VEGF) and related pathway elements combination of terms): VEGF, colorectal are critically important in the pathogenesis, cancer, mCRC, aflibercept, ziv-aflibercept. growth, and development of solid tumors. Studies were limited to those published in Inhibiting the VEGF signaling pathway is English. being investigated as a therapeutic strategy for Results: Phase 1 and 2 clinical trials of cancer, either by blockade of VEGF ligand aflibercept in advanced non-hematological binding or inhibition of the VEGF receptor. cancer showed acceptable safety and provided Aflibercept is a VEGF inhibitor that has been justification for further investigation. Four approved by the US Food and Drug phase 3 clinical trials were conducted to Administration for the treatment of macular evaluate aflibercept for

Journal

Oncology and TherapySpringer Journals

Published: Oct 16, 2013

References